Abstract
Comparison of maximal hyperemic myocardial blood flow response between regadenoson and adenosine: A quantitative positron emission tomography 13n-ammonia study
Highlights
For several decades, dipyridamole and adenosine were the main vasodilator stress agents in radionuclide myocardial perfusion imaging (MPI) worldwide due to their potent hyperemic effects
Christopoulos G (2019) Comparison of maximal hyperemic myocardial blood flow response between regadenoson and adenosine: A quantitative positron emission tomography 13N-ammonia study recruited by public advertising
There were no significant differences in resting or peak heart rate, systolic, or diastolic blood pressures, change in the parameters between baseline and hyperemia, or in peak rate-pressure product between regadenoson and adenosine groups (Table 1)
Summary
Dipyridamole and adenosine were the main vasodilator stress agents in radionuclide myocardial perfusion imaging (MPI) worldwide due to their potent hyperemic effects. In 2008, the United States Food and Drug Administration (FDA) approved regadenoson, a selective A2A adenosine agonist, for use as a pharmacologic stress agent in single photon emission computed tomography (SPECT) MPI. Regadenoson has gained widespread use for radionuclide MPI in the United States due to its many advantages [1,2]. Regadenoson has a safer profile in moderate to severe airway disease, compared other vasodilator stress agents [3,4,5]. The purpose of this study was to compare peak regadenoson vs peak adenosine absolute myocardial blood flow (MBF) and myocardial flow reserve (MFR) measurements by positron emission tomography (PET) 13N-ammonia (13N-NH3) in healthy human subjects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
